Module

Multitargeted Tyrosine Kinase Inhibitors: Clinical Advances, Synergistic Approaches, and Future Development

Source: Translating Science Into Clinical Practice: Recent Lessons in EGFR Inhibition, Multitargeted TKIs, and the Tumor Microenvironment

Multitargeted Tyrosine Kinase Inhibitors: Clinical Advances, Synergistic Approaches, and Future Development


Program Director: Ezra E. W. Cohen, MD, FRCPC

Faculty:

Ezra E. W. Cohen, MD, FRCPC
  • Ezra E. W. Cohen, MD, FRCPC

CME CREDIT INFORMATION

Release Date: 08/15/08

Expiration Date: 08/14/09


Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: Please log in to view status

Begin the Module

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the rationale for the use of single-target vs multitargeted tyrosine kinase inhibitors in the treatment of cancer patients
  • Review the results of clinical studies involving multitargeted tyrosine kinase inhibitors
  • Identify factors useful for the selection of tyrosine kinase inhibitors in specific patient populations

Topics covered include:

  • Introduction: Targeting Tyrosine Kinases in Tumor Cells
  • Role of RTKs in Tumor Biology
  • Sunitinib: Clinical Experience in RCC and GIST
  • Sorafenib: Clinical Experience in RCC and HCC
  • Axitinib Phase II Clinical Trials
  • Motesanib: Phase II Clinical Trials
  • Vandetanib: Phase II Clinical Trials
  • Vatalanib in mCRC
  • Pazopanib in Soft Tissue Sarcomas and Metastatic Breast Cancer
  • XL880 Targets MET/VEGFR-2
  • Conclusions
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.